Last reviewed · How we verify
NCT05223595
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Phase 1 trial testing Gentuximab in Metastatic Non-Small Cell Lung Cancer in 42 participants. Status unknown.
30 September 2023
Quick facts
| Lead sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 2 April 2021 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Gentuximab
Conditions studied
- Metastatic Non-Small Cell Lung Cancer — all drugs for Metastatic Non-Small Cell Lung Cancer →
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Metastatic Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05223595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Non-Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT05607550 — Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small · Phase 3 · active not recruiting
- NCT05364073 — Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Inclu · Phase 1 · active not recruiting
- NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina · Phase 2, PHASE3 · recruiting
- NCT04166487 — Plasma-Adapted First-Line Pembro In NSCLC · Phase 2 · active not recruiting
Other Changchun GeneScience Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07534176 — To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . · Phase 1 · not yet recruiting
- NCT07476586 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants · Phase 1 · not yet recruiting
- NCT07491289 — GS1-144 in Participants With Hepatic Impairment and Healthy Female · Phase 1 · not yet recruiting
- NCT07537231 — A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Fe · Phase 1 · not yet recruiting
- NCT07366866 — A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05223595 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changchun GeneScience Pharmaceutical Co., Ltd.
- Last refreshed: 4 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05223595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing